[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349729-105":59,"doc-detail-349729-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","targeting-the-ufl1-akt-cascade-suppresses-triple-negative-breast-cancer-progression","Targeting the UFL1-AKT cascade suppresses triple-negative breast cancer progression","","Triple-negative breast cancer (TNBC) is an aggressive disease with limited targeted options, largely constrained by chemoresistance and metastatic potential. The study investigates the UFMylation pathway, showing that AKT1 directly binds UFL1 and is UFMylated at Lys189/276/297, enhancing AKT phosphorylation and activation. AKT phosphorylates UFL1 at Thr426, forming a positive feedback loop that sustains pro-oncogenic activity and drives progression. Blocking the UFL1-AKT interaction with PDAU-TAT inhibits TNBC in vitro and in vivo, and elevated pT426 UFL1 associates with high pAKT in clinical specimens, supporting this axis as a therapeutic strategy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-the-ufl1-akt-cascade-suppresses-triple-negative-breast-cancer-progression/349729/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-the-ufl1-akt-cascade-suppresses-triple-negative-breast-cancer-progression/349729.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main mechanism linking UFL1 and AKT in TNBC progression?","Question",{"text":113,"@type":114},"AKT1 directly interacts with UFL1 and undergoes UFMylation at Lys189/276/297, which increases AKT phosphorylation and activation. AKT then phosphorylates UFL1 at Thr426, creating a positive feedback loop that sustains pro-oncogenic signaling.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which molecular sites on UFL1 and AKT are reported in the study?",{"text":118,"@type":114},"UFL1 is UFMylated on AKT at Lys189/276/297, and AKT phosphorylates UFL1 at Thr426. These modifications are tied to enhanced pathway activity and tumor progression.",{"name":120,"@type":111,"acceptedAnswer":121},"How does inhibiting the UFL1-AKT interaction affect TNBC?",{"text":122,"@type":114},"Disrupting the UFL1-AKT interaction using the specific peptide PDAU-TAT significantly inhibits TNBC progression in vitro and in vivo, indicating therapeutic potential of targeting this axis.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},349729,1790194559,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Article [https://doi.org/10.1038/s41467-026-68493-2](https://doi.org/10.1038/s41467-026-68493-2)  \nTargeting the UFL1-AKT cascade suppresses triple-negative breast cancer progression  \nReceived: 13 March 2025  \n\n| Accepted: 9 January 2026 |\n| --- |\n| |\n| Check for updates |\n\nXiao Yang1,2,9, Yalei Wen2,9, Xiuqing Ma2,9, Shengying Qin3,4,9, Yixia Liu2, Jiaqi Chen2, Haoxing Zhang 5, Colin R. Goding 6, Rutao Cui 7,8 & Tongzheng Liu 1,2   \nTriple-negative breast cancer (TNBC) is an aggressive and highly lethal disease with limited therapies. While UFL1-mediated UFMylation has been implicated in various diseases, its role in TNBC remains not fully understood. Here, we demonstrate that AKT1 directly interacts with UFL1 and undergoes UFMylation at Lys189/276/297. This modiﬁcation enhances AKT phosphorylation and activation, promoting tumor growth and chemoresistance in TNBC. In turn, AKT phosphorylates UFL1 at Thr426, establishing a positive feedback loop that sustains high activity of both pro-oncogenic regulators in TNBC. Disrupting the UFL1-AKT interaction using the speciﬁc peptide PDAU-TAT signiﬁcantly inhibits TNBC progression both in vitro and in vivo. Clinically, elevated pT426 UFL1 correlates with high pAKT in TNBC specimens. These ﬁndings uncover a crucial UFL1-AKT positive feedback loop that drives TNBC progression and suggest that targeting this axis could offer a promising therapeutic strategy for TNBC and potentially other aggressive cancers characterized by upregulated UFL1 and AKT activation.  \nTriple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) expression1. The clinical management of TNBC is challenging due to the lack of targeted therapies. While standard chemotherapies such as cisplatin and paclitaxel are commonly used, their effectiveness is limited by the frequent development of chemoresistance and the higher metastatic potential ofTNBC2. Therefore, there is an urgent need for novel targeted therapies that may signiﬁcantly improve clinical outcomes for patients with TNBC.  \nUFMylation, a recently identiﬁed ubiquitin-like modiﬁcation mediated by the E3 ligase UFL1, plays a crucial role in diverse cellular processes, including endoplasmic reticulum (ER) homeostasis3,4, immunity5,6, and DNA damage response7,8. Dysregulation of the  \nUFMylation system has been associated with several diseases such as anemia and cancer9–12. Emerging evidence suggests that UFL1 can act either as a tumor suppressor or an oncogene, depending on the speciﬁc tumor context. For instance, UFL1 has been shown to ufmylate p53, thereby antagonizing MDM2-mediated ubiquitination, which stabilizes p53 and enhances its tumor-suppressive function in colorectal cancer10. Additionally, the loss of UFL1/UFBP1 in hepatocytes has been linked to liver carcinogenesis13. Conversely, UFL1-mediated UFMylation of the nuclear receptor coactivator ASC1 is crucial for ERα transactivation in response to 17β-estradiol, promoting ERα -mediated tumor formation in vivo9. Furthermore, UFMylation of ERα enhances its stability and transactivation, contributing to the development of ER+ breast cancer14. However, despite these insights, the substrates of UFMylation and its precise biological functions in TNBC,  \n1Department of General Surgery, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, China. 2College of Pharmacy, Jinan University, Guangzhou, China. 3Department of Oncology, The First Afﬁliated Hospital of Jinan University, Guangzhou, China. 4Clinical Medical Research Institute, Jinan University, Guangzhou, China. 5Guangdong Provincial Key Laboratory of Genome Stability and Disease Prevention, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, China. 6Ludwig Institute for Cancer Research, University of Oxford, Headington, Oxford, UK. 7Zhejiang University School of Medici","cbCaifPuaMbGTAlJ","https://ap.wps.com/l/cbCaifPuaMbGTAlJ","pdf",11211989,16,"English","# Background\n## Triple-negative breast cancer and clinical challenges\n## UFMylation and UFL1 in cancer biology\n## AKT activation and regulation\n# Key Findings\n## AKT1–UFL1 interaction and UFMylation sites\n## Positive feedback loop via UFL1 Thr426 phosphorylation\n## Therapeutic disruption using PDAU-TAT","[{\"question\":\"What is the main mechanism linking UFL1 and AKT in TNBC progression?\",\"answer\":\"AKT1 directly interacts with UFL1 and undergoes UFMylation at Lys189/276/297, which increases AKT phosphorylation and activation. AKT then phosphorylates UFL1 at Thr426, creating a positive feedback loop that sustains pro-oncogenic signaling.\"},{\"question\":\"Which molecular sites on UFL1 and AKT are reported in the study?\",\"answer\":\"UFL1 is UFMylated on AKT at Lys189/276/297, and AKT phosphorylates UFL1 at Thr426. These modifications are tied to enhanced pathway activity and tumor progression.\"},{\"question\":\"How does inhibiting the UFL1-AKT interaction affect TNBC?\",\"answer\":\"Disrupting the UFL1-AKT interaction using the specific peptide PDAU-TAT significantly inhibits TNBC progression in vitro and in vivo, indicating therapeutic potential of targeting this axis.\"}]","Targeting the UFL1-AKT cascade suppresses triple-negative breast cancer progression | PDF",1790085279,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a0b577c5899bf910a26da8a272b1b35.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b16d5fc75689ec470d435247ed18418.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a902c404ae77eb5bb77b1b3b2d3d07fc.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ccedf6f14bfb64224d81159e43ea317.webp",980,1301]